dismissedMAR122026_01B52032026-03-12 · appeal · SCOPS Service Center

This is an AAO appeal decision — a case denied once and appealed. It shows how the framework is applied; it is not the filing population.

The Beneficiary, working as a study management associate II, proposes to oversee and manage global clinical trials for novel cancer therapeutics, ensuring regulatory compliance and data integrity to support FDA approval of new hematologic malignancy therapies.

Field: clinical trial management / oncology research administration · Read the decision (uscis.gov)

Prong 1 — national importancenot established · dispositive

“merely working in an important field is insufficient to establish the national importance of the proposed endeavor.”

“the Petitioner has not demonstrated that the economic implications and advancements resulting from the Petitioner's operations would be directly attributable to the Beneficiary's particular role as a study management associate II.”

“the evidence does not sufficiently demonstrate how the Beneficiary as a single employee would affect the industry more broadly.”

“the authors do not offer sufficient detail regarding the Beneficiary's specific proposed endeavor and its national importance.”

“the Petitioner has not shown that the Beneficiary's specific endeavor he proposes to undertake stands to sufficiently extend beyond the Petitioner's clients, partners, or consumers.”

“the Petitioner did not show how the Beneficiary's position has significant potential to employ U.S. workers or otherwise offer substantial positive economic effects for our nation.”

AAO decision text

How the evidence was treated

recommendation letter · discounted
“the authors do not offer sufficient detail regarding the Beneficiary's specific proposed endeavor and its national importance.”
AAO decision text
resume experience · discounted
“these experiences are misplaced in the context of the first Dhanasar prong.”
AAO decision text
other · discounted
“the Petitioner has not provided similar evidence, such as the type of expert opinion evidence or letters from government entities detailing how the Beneficiary's endeavor impacts a matter that is a subject of national initiatives.”
AAO decision text

Where this case turned

Economic claims unsupported · p1 — job/revenue projections with no corroborating basis
Employer-specific benefit · p1 — "work furthers my company's product" — value accrues to one firm
Field importance conflated with endeavor · p1 — argues the field matters, not the specific endeavor
Letters conclusory · p1 — letters praise skills in general terms without tracing specific impact

2,501coded decisions carry the failure named in this record. A placement shows where your profile sits among them, not what it predicts.See where your profile sits — 90 seconds →

Notable

SCOPS had already conceded substantial merit of the endeavor (cancer therapeutics clinical trial management), so the sole contested issue on appeal was national importance under prong 1. The AAO explicitly noted the absence of government-entity letters or expert letters comparable to those credited in Dhanasar itself, and faulted the petitioner for failing to distinguish the Beneficiary's individual role from the broader team and employer operations.

What this case teaches

Analyst reading of the decision text.

Decisive factor

The therapies' national importance belonged to the employer; the beneficiary was one member of a project-management team whose duties supported company operations, so his specific endeavor showed no broader impact (prong one).

Transferable lesson

In an employer-filed NIW, the beneficiary's own role must carry the impact; managing trials for important therapies attributes the significance to the company, and duty-listing letters are prong-2 material.

Endeavor framing

moderate

National-importance theory

public_health · government_interest · field_advancement

Evidence targeting

person_focused

Cases in adjacent profiles

← Back to the case explorer